

## Editorial Board of Trend in Bio/Pharmaceutical Industry

### Editor in Chief

Wang, Jianxin *Novartis, USA*

### Board of Scientific Editors

An, Songzhu *Amgen, USA*

Feng, Gensheng *Burnham Inst. USA*

Han, Jun *Barr Pharma., USA*

Li, Bin *Chempartner, China*

Li, Hui *Pfizer, China*

Li, Yuling *Human Genome  
Sciences, USA*

Liu, Chuan *Medidata, USA*

Mo, Chengjun *Medimmune, USA*

Shi, Li *Genzyme, USA*

Wang, Deqian *Bayer, USA*

Wei, Yingfei *3Sbio, China*

Wu, Jinzi *GSK, USA*

Yang, Dajun *Ascera, USA*

Yang, Pei *Ascenta, USA*

Yang, Naibo *Biochain, USA*

Yu, Guoliang *Epitomics, USA*

### Art Director

Li, Xiaojun *CA State, USA*

### Participating Organizations

Members of ALL-CABPA

Chinese-American BioPharmaceutical  
Society (<http://www.cabsweb.org>)

Chinese-American Biopharmaceutical  
Association (<http://www.cabaweg.org>)

Chinese Biopharmaceutical Association  
(<http://www.cba-usa.org>)

Seattle Chinese Biomedical Association  
(<http://www.scbahome.org/>)

&

BeyHelix (<http://www.bayhelix.org>)

### Partners in Publication


Chinese Pharmaceutical Journal, China  
Progress in Pharmaceutical Science,  
China

### Contact Us

**TBI online:** [tbi.cabsweb.org](http://tbi.cabsweb.org)

**Email:** [tbi@tbiweb.org](mailto:tbi@tbiweb.org)

## Letter from Editor



### Dear friends

I have been watching the Beijing Olympics from NBC in the past few weeks. Having spent over 20 years in that city, I was still stunned by the spectacular stadiums, breath-taking ceremony and the demonstration of a civilization, old and young, in front of the world. From the eyes of the thousands of volunteers, you can see the aspiration for a brighter future and the determination to make that into a reality. The games have ended while the excitement and true impact will emerge in the future.

Similar feelings came to me when I read through this issue of 'Trends in Bio/Pharmaceutical Industry (TBI). For the first time, we were able to include annual meeting reports from all major biotech/pharmaceutical hubs in the US, including Boston, New Jersey, Washington DC, Philadelphia, San Diego and San Francisco. Organized by member associations of the newly formed Alliances of Chinese American Biotechnology and Pharmaceutical Associations (ALL-CABPA) and their like-minded sister organizations, these meetings covered a broad range of topics with high caliber presentations and panel discussions.

The success of the 10th Shanghai Bio-forum and 13th CBA annual meeting in Shanghai also showcased that the influence we collectively put together has moved beyond the US. It is a challenging and exciting time for the industry as a whole and this was well reflected in the subjects each annual meeting chose to cover. I hope by having their reports together will inspire greater thinking and discussion from our readers as well.

Happy reading!

Hui Li  
Editor